Loading clinical trials...
Loading clinical trials...
An Open-Label, Phase 1/2 Study to Evaluate Safety, Efficacy, and Pharmacokinetics of EU101, an Agonistic Anti-CD137 (4-1BB) Monoclonal Antibody in Patients With Advanced Solid Tumors
Conditions
Interventions
EU101
Locations
6
United States
Fox Chase Cancer Center
Philadelphia, Pennsylvania, United States
Mary Crowley Center
Dallas, Texas, United States
National Cancer Center
Ilsan, South Korea
Samsung Seoul Hospital
Seoul, South Korea
Seoul Asan
Seoul, South Korea
Severance Hospital
Seoul, South Korea
Start Date
May 31, 2021
Primary Completion Date
September 1, 2025
Completion Date
December 1, 2025
Last Updated
March 15, 2024
NCT06144671
NCT04570423
NCT06132828
NCT07177937
NCT07489378
NCT06926283
Lead Sponsor
Eutilex
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions